The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers
- PMID: 41549
- PMCID: PMC1429840
- DOI: 10.1111/j.1365-2125.1979.tb04717.x
The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers
Abstract
1. The effect of spontaneous changes in urinary pH on renal excretion and plasma concentration of mexiletine has been examined during chronic administration of subtherapeutic doses of the drug to healthy volunteers. 2. Significant correlations were found between urinary pH and the plasma concentration and renal excretion of mexiletine. 3. Prediction of plasma mexiletine concentrations from our data suggests that the amount of mexiletine in plasma would increase by more than 50% following a rise in urinary pH similar to that which occurred spontaneously in our subjects. 4. Factors which influence urinary pH should be considered when the dosage of mexiletine is chosen. Extremes of urinary pH may account for some cases of inefficacy of the drug, and for the occurrence of unwanted effects at conventional doses.
Similar articles
-
Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.Br J Clin Pharmacol. 1983 Sep;16(3):281-4. doi: 10.1111/j.1365-2125.1983.tb02162.x. Br J Clin Pharmacol. 1983. PMID: 6626420 Free PMC article.
-
Variable pharmacokinetics of mexiletine.Postgrad Med J. 1977;53 Suppl 1:56-9. Postgrad Med J. 1977. PMID: 17856 No abstract available.
-
The relationship between plasma levels, salivary concentrations and urinary excretion rates of mexiletene [proceedings].J Pharm Pharmacol. 1976 Dec;28 Suppl:58P. J Pharm Pharmacol. 1976. PMID: 12335 No abstract available.
-
Baseline pharmacology, electrophysiology and pharmacokinetics of mexiletine.Acta Cardiol Suppl. 1980;(25):45-53. Acta Cardiol Suppl. 1980. PMID: 6990666 Review.
-
Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.Drugs. 1979 Mar;17(3):161-81. doi: 10.2165/00003495-197917030-00003. Drugs. 1979. PMID: 378646 Review.
Cited by
-
Enhanced metabolism of mexiletine after phenytoin administration.Br J Clin Pharmacol. 1982 Aug;14(2):219-23. doi: 10.1111/j.1365-2125.1982.tb01965.x. Br J Clin Pharmacol. 1982. PMID: 7104173 Free PMC article.
-
Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.Postgrad Med J. 1985 Aug;61(718):665-77. doi: 10.1136/pgmj.61.718.665. Postgrad Med J. 1985. PMID: 3898053 Free PMC article. Review. No abstract available.
-
The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.Br J Clin Pharmacol. 1991 Oct;32(4):459-66. doi: 10.1111/j.1365-2125.1991.tb03931.x. Br J Clin Pharmacol. 1991. PMID: 1958440 Free PMC article.
-
Clinical pharmacokinetics of mexiletine.Clin Pharmacokinet. 1999 Nov;37(5):361-84. doi: 10.2165/00003088-199937050-00002. Clin Pharmacokinet. 1999. PMID: 10589372 Review.
-
Pharmacokinetics of mexiletine in renal insufficiency.Br J Clin Pharmacol. 1982 Sep;14(3):431-5. doi: 10.1111/j.1365-2125.1982.tb02003.x. Br J Clin Pharmacol. 1982. PMID: 7126416 Free PMC article.
References
-
- Br J Clin Pharmacol. 1978 Aug;6(2):103-8 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources